Teva Raises Guidance As Generics Enjoy Solid Growth In Q2
Biosimilars Business Boosted By Adalimumab Launch In US Ahead Of Ustekinumab Opportunity
• By David Wallace
Teva reported double-digit growth for generics in the second quarter • Source: Shutterstock 
